India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in India until 2026. It's a big victory for the US drugmaker in a market that has the world's largest number of pneumonia cases, a lung disease that kills nearly a million children a year globally. The decision also has ...
India's patent to Pfizer will bar poor's access to pneumonia vaccine abroad
Pfizer's vaccine protects children and adults from 13 types of pneumococcal bacteria
Reuters Last Updated at August 23, 2017 14:06 IST